{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:26:35Z","timestamp":1795008395411,"version":"4.9.1"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Human immunodeficiency virus (HIV) is a primary global health concern, affecting an estimated 38 million individuals as of 2023. While HIV is best known for its immunosuppressive effects, its cardiovascular implications are equally significant. HIV infection contributes to cardiovascular disease (CVD) through chronic immune activation, systemic inflammation, endothelial dysfunction, oxidative stress, and coagulopathy. These mechanisms increase the risk of myocardial infarction, cardiomyopathy, heart failure, pulmonary hypertension, and thrombotic events in people living with HIV (PLWH). However, the advent of Highly Active Antiretroviral Therapy (HAART) has transformed HIV from a fatal illness into a chronic, manageable condition. Despite this progress, HAART \u2013 particularly regimens involving protease inhibitors and certain nucleoside reverse transcriptase inhibitors \u2013 has introduced new cardiovascular challenges. These include dyslipidemia, insulin resistance, mitochondrial toxicity, and altered adipose tissue distribution, all of which further elevate cardiovascular risk.<\/jats:p>\n                  <jats:p>Additionally, HAART modifies immune and metabolic pathways, potentially exacerbating underlying HIV-associated cardiovascular mechanisms. Emerging research into microbial translocation and gut dysbiosis also points to complex interactions between HIV, HAART, and cardiovascular outcomes. As survival improves for PLWH, cardiologists and infectious disease specialists must collaborate to address both the direct effects of HIV and the unintended cardiovascular consequences of its treatment. The authors\u2019 review explores the dual impact of HIV and HAART on the cardiovascular system, emphasizing the importance of integrated care, early risk assessment, and therapeutic strategies tailored to the unique cardiovascular profile of PLWH.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003465","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:00:14Z","timestamp":1749549614000},"page":"5012-5028","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The heart and HIV therapy: exploring the dual cardiovascular impact of antiretroviral treatment \u2013 a narrative review"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0249-1865","authenticated-orcid":false,"given":"Chukwuka","family":"Elendu","sequence":"first","affiliation":[{"name":"Federal University Teaching Hospital, Owerri, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Otobrise","sequence":"additional","affiliation":[{"name":"University of Medical Sciences, Ondo, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Blewusi","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzubechukwu A.","family":"Iheanetu","sequence":"additional","affiliation":[{"name":"V. N. Karazin Kharkiv National University, Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious A.","family":"Olaofe","sequence":"additional","affiliation":[{"name":"Kyiv Medical University, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nwamaka C.","family":"Bob-Ume","sequence":"additional","affiliation":[{"name":"All Saints University School of Medicine, St Vincent & The Grenadines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila A.","family":"Suleiman","sequence":"additional","affiliation":[{"name":"Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemilah I.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Nahda University, Beni Suef, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barakat I.","family":"Ibikunle","sequence":"additional","affiliation":[{"name":"University of Szeged, Albert Szent-Gy\u00f6rgyi Medical School, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peace","family":"Mordi","sequence":"additional","affiliation":[{"name":"Gannan Medical University, Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Olabode","sequence":"additional","affiliation":[{"name":"Babcock University, Ilishan-Remo, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde M.","family":"Ogungbade","sequence":"additional","affiliation":[{"name":"Afe Babalola University, Ado-Ekiti, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funmilayo G.","family":"Adelakun","sequence":"additional","affiliation":[{"name":"Babcock University, Ilishan-Remo, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris N.","family":"Idion","sequence":"additional","affiliation":[{"name":"Delta State University Teaching Hospital, Oghara, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u2019Adatu I.","family":"Kure","sequence":"additional","affiliation":[{"name":"American University of Antigua, St. John's, Antigua"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaobi S.","family":"Ikedilo","sequence":"additional","affiliation":[{"name":"Piedmont Athens Regional Medical Centre, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace D.","family":"Ogunkoya","sequence":"additional","affiliation":[{"name":"Bogomolets National Medical University, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolore Aminat","family":"Ajakaye","sequence":"additional","affiliation":[{"name":"Regions Healthcare Hospitals and Specialist Clinics, Mgbrichi, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaeze B.","family":"Eze","sequence":"additional","affiliation":[{"name":"University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obinna D.","family":"Nwaizuzu","sequence":"additional","affiliation":[{"name":"University of Nigeria, Nsukka, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/COH.0000000000000702","article-title":"Cardiovascular toxicity of contemporary antiretroviral therapy","volume":"16","author":"Vos","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijid.2021.02.045","article-title":"Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy","volume":"105","author":"Chen","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid, and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"e39831","DOI":"10.1097\/MD.0000000000039831","article-title":"The relationship between HIV\/AIDS and coronary heart disease: a bibliometric analysis","volume":"103","author":"Cai","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/pathogens12070925","article-title":"Evaluation of lipid profile and intima-media thickness in antiretroviral-experienced HIV-infected patients treated with protease inhibitor-based regimens versus protease inhibitor-sparing regimens","volume":"12","author":"Martini","year":"2023","journal-title":"Pathogens"},{"key":"R9-20250806","doi-asserted-by":"crossref","DOI":"10.1007\/s11904-016-0301-4","article-title":"Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults","author":"Kaplan","year":"2016","journal-title":"HIV\/AIDS Rep"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11904-018-0400-5","article-title":"HIV and cardiovascular disease: update on clinical events, special populations, and novel biomarkers","volume":"15","author":"So-Armah","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-019-0497-7","article-title":"Cardiovascular disease risk in an urban African population: a cross-sectional analysis on the role of HIV and antiretroviral treatment","volume":"16","author":"Vos","year":"2019","journal-title":"Retrovirology"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eimc.2018.09.015","article-title":"Rate of cardiovascular, renal, and bone disease and their major risk factors in HIV-infected individuals on antiretroviral therapy in Spain","volume":"37","author":"Knobel","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/14740338.4.6.1017","article-title":"Cardiovascular disease and toxicities related to HIV infection and its therapies","volume":"4","author":"Zareba","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/eri.12.53","article-title":"HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults","volume":"10","author":"Lipshultz","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jinf.2008.02.006","article-title":"Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy","volume":"57","author":"Calza","year":"2008","journal-title":"J Infect"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3855\/jidc.12519","article-title":"Cumulative effects of hypertriglyceridemia in HIV-infected patients switching from NNRTIs to PI-based antiretroviral therapy","volume":"16","author":"Zhang","year":"2022","journal-title":"J Infect Dev Ctries"},{"key":"R18-20250806","first-page":"82","article-title":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents","volume":"35","author":"Byonanebye","year":"2021","journal-title":"AIDS"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/QAI.0000000000002357","article-title":"Brief report: integrase strand transfer inhibitors are associated with a lower risk of incident cardiovascular disease in people living with HIV","volume":"84","author":"O\u2019Halloran","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/jac\/dky145","article-title":"Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors","volume":"73","author":"Bakal","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"e00000","DOI":"10.1097\/MD.0000000000025236","article-title":"Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: prevalence and associated factors","volume":"100","author":"Hamooya","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0956462420972855","article-title":"Assessment of atherosclerotic cardiovascular disease risks among people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting","volume":"32","author":"Tiarukkitsagul","year":"2021","journal-title":"Tiarukkitsagul J, Sungkanuparph S Int J STD AIDS"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2018.10.011","article-title":"Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: the AGING POSITIVE study","volume":"79","author":"Serr\u00e3o","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.diabet.2019.02.008","article-title":"Diabetes and dyslipidemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients","volume":"45","author":"Bastard","year":"2019","journal-title":"Diabetes Metab"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1186\/s12889-019-7496-4","article-title":"Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross-sectional study","volume":"19","author":"Agu","year":"2019","journal-title":"BMC Public Health"},{"key":"R26-20250806","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/25787489.2020.1724749","article-title":"Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy","volume":"20","author":"Calza","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/s12879-019-4446-9","article-title":"Association between lipodystrophy and length of exposure to ARTs in adult HIV-1-infected patients in montreal","volume":"19","author":"Alikhani","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R28-20250806","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0000000000003019","article-title":"Brief report: evaluation of inflammation and atherogenesis biomarkers through 148 weeks postswitch to dolutegravir and rilpivirine in SWORD-1\/SWORD-2","volume":"91","author":"Llibre","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-20250806","doi-asserted-by":"crossref","first-page":"e0","DOI":"10.1002\/jia2.26123","article-title":"Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States","volume":"26","author":"Rebeiro","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/hiv.13273","article-title":"Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium","volume":"23","author":"Byonanebye","year":"2022","journal-title":"HIV Med"},{"key":"R31-20250806","doi-asserted-by":"crossref","DOI":"10.3390\/v14081677","article-title":"Changes in body mass index after the initiation of antiretroviral treatment: differences by class of core drug","author":"Pantazis","year":"2022","journal-title":"Viruses"},{"key":"R32-20250806","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/QAD.0000000000000946","article-title":"Serum oxidized low-density lipoprotein decreases in response to statin therapy and is independently associated with reductions in coronary plaque in patients with HIV","volume":"30","author":"Nou","year":"2016","journal-title":"AIDS"},{"key":"R33-20250806","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cjca.2017.07.015","article-title":"Association between circulating oxidized LDL and atherosclerotic cardiovascular disease: a meta-analysis of observational studies","volume":"33","author":"Gao","year":"2017","journal-title":"Liu J Can J Cardiol."},{"key":"R34-20250806","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation","volume":"69","author":"Zidar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-20250806","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1468-1293.2009.00766.x","article-title":"Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation","volume":"11","author":"Parra","year":"2010","journal-title":"HIV Med"},{"key":"R36-20250806","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"R37-20250806","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.amjcard.2004.11.004","article-title":"Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy","volume":"95","author":"Grover","year":"2005","journal-title":"Mukherjee J Am J Cardiol"},{"key":"R38-20250806","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.118.036211","article-title":"Time to recognize HIV infection as a major cardiovascular risk factor. hsue PY, waters DD","volume":"138","author":"Hsue","year":"2018","journal-title":"Circulation"},{"key":"R39-20250806","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/QAD.0b013e32834be088","article-title":"Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy","volume":"25","author":"Baker","year":"2011","journal-title":"AIDS"},{"key":"R40-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0000000000002385","article-title":"Comorbidities of HIV infection: role of nef-induced impairment of cholesterol metabolism and lipid raft functionality","volume":"34","author":"Sviridov","year":"2020","journal-title":"AIDS"},{"key":"R41-20250806","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2004.07.035","article-title":"Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals","volume":"178","author":"Carpentier","year":"2005","journal-title":"Atherosclerosis"},{"key":"R42-20250806","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059514","article-title":"HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes","volume":"8","author":"Zha","year":"2013","journal-title":"PLoS One"},{"key":"R43-20250806","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J Hepatol"},{"key":"R44-20250806","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004987","article-title":"Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial","volume":"6","author":"Baker","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R45-20250806","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"R46-20250806","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3851\/IMP3051","article-title":"Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study","volume":"21","author":"Kamara","year":"2016","journal-title":"Antivir Ther"},{"key":"R47-20250806","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1124\/jpet.110.168484","article-title":"Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways","volume":"334","author":"Cao","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R48-20250806","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4038\/cmj.v61i2.8300","article-title":"Trends and risk factors for obesity among HIV positive Nigerians on antiretroviral therapy","volume":"61","author":"Ezechi","year":"2016","journal-title":"Ceylon Med J"},{"key":"R49-20250806","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","article-title":"Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s","volume":"62","author":"McComsey","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R50-20250806","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"R51-20250806","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209911","article-title":"Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: a substudy of the NEAT001\/ANRS143 randomised trial","volume":"14","author":"Bernardino","year":"2019","journal-title":"PLoS One"},{"key":"R52-20250806","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open-label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"R53-20250806","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"R54-20250806","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief Report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R55-20250806","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R56-20250806","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R57-20250806","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25732","article-title":"Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study","volume":"24","author":"Mart\u00ednez-Sanz","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"R58-20250806","article-title":"Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-naive persons starting INSTI-based antiretroviral therapy","volume":"6","author":"Galdamez","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R59-20250806","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R60-20250806","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000003584","article-title":"Combination antiretroviral therapy and hypertensive disorders of pregnancy","volume":"134","author":"Saums","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R61-20250806","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089088","article-title":"Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV\/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study","volume":"9","author":"Domingo","year":"2014","journal-title":"PLoS One"},{"key":"R62-20250806","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077138","article-title":"HIV lipodystrophy in participants randomised to lopinavir\/ritonavir (LPV\/r) +2-3 nucleoside\/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV\/r + raltegravir as second-line antiretroviral therapy","volume":"8","author":"Martin","year":"2013","journal-title":"PLoS One"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:16:42Z","timestamp":1754497002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003465","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"2025-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}